Grunenthal Acquires Global Rights for Qutenza(R)

PR76118

AACHEN, Germany , Nov. 5, 2018 /PRNewswire=KYODO JBN/ --

Grunenthal, the science-focused pharmaceutical company based in Germany,

announced today that it has acquired additional global commercial rights for

the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc

(USA). Grunenthal is now the sole owner of Qutenza(R) worldwide, including the

US, Latin America, Asia and Australia. Grunenthal had already acquired

exclusive commercial rights for Europe, Middle East and Africa in December 2016.

"As a leader in pain research and management, we're dedicated to providing

solutions for patients with high unmet medical needs. Qutenza(R) is a perfect

strategic fit, as it complements our existing pain portfolio and is a real

alternative to the current standard of care," says Gabriel Baertschi,

Grunenthal's Chief Executive Officer.

Qutenza(R) is a highly effective pain product. A single, 1-hour, localised

treatment with this patch may provide at least 3 months of relief from for

example post-shingles nerve pain. Grunenthal will aim to make Qutenza(R)   

available to patients worldwide. In territories where the company does not have

a presence of its own such as Asia and Australia, Grunenthal will look to

partner or out-license Qutenza(R).

Grunenthal continues executing its growth strategy and has been expanding its

pain portfolio by a series of acquisitions including European rights to

Nexium(R), the global (ex US and Japan) rights to Vimovo(R) and global (ex

Japan) rights to Zomig(R). The company has signed deals with a total value of

more than US$ 1.3 billion since 2016.

About Qutenza(R)

Qutenza(R)(capsaicin) 8% patch is approved in the US for the management of

neuropathic pain associated with postherpetic neuralgia. A single, 1-hour,

localized treatment with Qutenza(R) may provide at least 3 months of relief

from for example post-shingles nerve pain (PHN). In Europe, Qutenza(R) is

approved by the European Medicines Agency for the treatment of peripheral

neuropathic pain in adults, either alone or in combination with other pain

medicines. The 8% capsaicin patch delivers a high dose of capsaicin directly to

the damaged nerves in the skin that are the source of neuropathic pain. Applied

to the area of pain, the capsaicin reduces the spontaneous activity and

consequently reduces the neuropathic pain intensity. Important safety

information can be found here: http://www.qutenza.com and

http://www.ema.europa.eu/documents/product-information/qutenza-epar-product-information_en.pdf

About Grunenthal

Grunenthal is an entrepreneurial, science-based pharmaceutical company

specialized in pain, gout and inflammation. Our ambition is to deliver four to

five new products to patients in diseases with high unmet medical need by 2022

and become a EUR 2 bn company. We are a fully integrated research & development

company with a long track record of bringing innovative pain treatments and

state-of-the-art technologies to patients. By sustainably investing in our R&D

above the industrial average, we are strongly committed to innovation.

Grunenthal is an independent, family-owned company headquartered in Aachen,

Germany. We are present in approx. 30 countries with affiliates in Europe,

Latin America and the US. Our products are sold in more than 100 countries and

approx. 5,200 employees are working for  Grünenthal worldwide. In 2017,

Grunenthal achieved revenues of approx. EUR 1.3 bn.

More information: http://www.grunenthal.com

Follow us on:

LinkedIn: Grunenthal Group [http://www.linkedin.com/company/grunenthal_164071/]

Twitter: @grunenthalgroup [https://twitter.com/grunenthalgroup]

Instagram: gruenenthal [https://www.instagram.com/gruenenthal/]

For further information, please contact:

Stipan Kraeala, Head Global Communications

Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com

Grunenthal GmbH, 52099 Aachen, Germany

Kerstin Nacken, Head Editorial Management and Media Relations

Tel.: +49 241 569-2710, Kerstin.Nacken@grunenthal.com

Grunenthal GmbH, 52099 Aachen, Germany

Source: Grunenthal Group